353 related articles for article (PubMed ID: 36399953)
1. Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review.
Di Lauro V; Barchiesi G; Martorana F; Zucchini G; Muratore M; Fontanella C; Arpino G; Del Mastro L; Giuliano M; Puglisi F; De Laurentiis M
ESMO Open; 2022 Dec; 7(6):100629. PubMed ID: 36399953
[TBL] [Abstract][Full Text] [Related]
2. Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.
Desnoyers A; Nadler MB; Kumar V; Saleh R; Amir E
Cancer Treat Rev; 2020 Nov; 90():102086. PubMed ID: 32861975
[TBL] [Abstract][Full Text] [Related]
3. CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib.
Eggersmann TK; Degenhardt T; Gluz O; Wuerstlein R; Harbeck N
BioDrugs; 2019 Apr; 33(2):125-135. PubMed ID: 30847853
[TBL] [Abstract][Full Text] [Related]
4. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
Cersosimo RJ
Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
[TBL] [Abstract][Full Text] [Related]
5. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Kwapisz D
Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
[TBL] [Abstract][Full Text] [Related]
6. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
Spring LM; Zangardi ML; Moy B; Bardia A
Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
[TBL] [Abstract][Full Text] [Related]
7. Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies.
Kwapisz D
Breast Cancer; 2018 Sep; 25(5):506-516. PubMed ID: 29700711
[TBL] [Abstract][Full Text] [Related]
8. Comparative overall survival of CDK4/6 inhibitors in combination with endocrine therapy in advanced breast cancer.
Kappel C; Elliott MJ; Kumar V; Nadler MB; Desnoyers A; Amir E
Sci Rep; 2024 Feb; 14(1):3129. PubMed ID: 38326452
[TBL] [Abstract][Full Text] [Related]
9. Real-World Treatment Patterns and Clinical Outcomes among Patients Receiving CDK4/6 Inhibitors for Metastatic Breast Cancer in a Canadian Setting Using AI-Extracted Data.
Moulson R; Feugère G; Moreira-Lucas TS; Dequen F; Weiss J; Smith J; Brezden-Masley C
Curr Oncol; 2024 Apr; 31(4):2172-2184. PubMed ID: 38668064
[TBL] [Abstract][Full Text] [Related]
10. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany.
Schneeweiss A; Ettl J; Lüftner D; Beckmann MW; Belleville E; Fasching PA; Fehm TN; Geberth M; Häberle L; Hadji P; Hartkopf AD; Hielscher C; Huober J; Ruckhäberle E; Janni W; Kolberg HC; Kurbacher CM; Klein E; Lux MP; Müller V; Nabieva N; Overkamp F; Tesch H; Laakmann E; Taran FA; Seitz J; Thomssen C; Untch M; Wimberger P; Wuerstlein R; Volz B; Wallwiener D; Wallwiener M; Brucker SY
Breast; 2020 Dec; 54():88-95. PubMed ID: 32956934
[TBL] [Abstract][Full Text] [Related]
11. Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor-Positive, ERBB2-Negative Breast Cancer: A Review.
O'Sullivan CC; Clarke R; Goetz MP; Robertson J
JAMA Oncol; 2023 Sep; 9(9):1273-1282. PubMed ID: 37382948
[TBL] [Abstract][Full Text] [Related]
12. Targeting CDK4/6 pathways and beyond in breast cancer.
Ribnikar D; Volovat SR; Cardoso F
Breast; 2019 Feb; 43():8-17. PubMed ID: 30359883
[TBL] [Abstract][Full Text] [Related]
13. CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update.
O'Sullivan CC
Expert Opin Pharmacother; 2016 Aug; 17(12):1657-67. PubMed ID: 27322766
[TBL] [Abstract][Full Text] [Related]
14. Systematic literature review of real-world evidence for treatments in HR+/HER2- second-line LABC/mBC after first-line treatment with CDK4/6i.
Lambert V; Kane S; Howidi B; Nguyen BN; Chandiwana D; Wu Y; Edwards M; Samjoo IA
BMC Cancer; 2024 May; 24(1):631. PubMed ID: 38783218
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, safety and toxicity management of adjuvant abemaciclib in early stage HR+/HER2- high-risk breast cancer.
Sammons S; Moore H; Cushman J; Hamilton E
Expert Rev Anticancer Ther; 2022 Aug; 22(8):805-814. PubMed ID: 35737886
[TBL] [Abstract][Full Text] [Related]
16. Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment.
Parylo S; Vennepureddy A; Dhar V; Patibandla P; Sokoloff A
J Oncol Pharm Pract; 2019 Jan; 25(1):110-129. PubMed ID: 29726787
[TBL] [Abstract][Full Text] [Related]
17. Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting.
Price GL; Sudharshan L; Ryan P; Rajkumar J; Sheffield KM; Nash Smyth E; Morato Guimaraes C; Rybowski S; Cuyun Carter G; Gathirua-Mwangi WG; Huang YJ
Curr Med Res Opin; 2022 Aug; 38(8):1319-1331. PubMed ID: 35535675
[TBL] [Abstract][Full Text] [Related]
18. The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer.
Shah AN; Cristofanilli M
Curr Treat Options Oncol; 2017 Jan; 18(1):6. PubMed ID: 28197838
[TBL] [Abstract][Full Text] [Related]
19. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
[TBL] [Abstract][Full Text] [Related]
20. CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib.
Laderian B; Fojo T
Semin Oncol; 2017 Dec; 44(6):395-403. PubMed ID: 29935901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]